Immune Pharmaceuticals signs letter of intent with Pint Pharma regarding license and commercialization of Ceplene in Latin America. Immune Pharmaceuticals Inc. announced today that it has entered into a letter of intent with Pint Pharma GmnH, a pharmaceutical company focused on Latin America and other markets, which binds the parties to seek agreement regarding an exclusive license by…